For years, dermatology health care providers (HCPs) have known that psoriasis is rarely "just" a skin condition. It’s a systemic inflammatory battle that often brings along unwanted reinforcements: obesity, type 2 diabetes, and a significantly higher risk of heart disease. In fact, patients with severe psoriasis face up to a 70% greater risk of stroke or premature mortality.
Recently, the National Psoriasis Foundation (NPF) Medical Board changed the conversation by publishing a groundbreaking primer in JAMA Dermatology. The verdict? GLP-1 receptor agonists (GLP-1RAs), the medications currently known for weight loss, might be a game-changer for psoriatic disease.
We’ve long understood the link between adipose tissue (fat) and inflammation. However, the new NPF manuscript highlights that GLP-1RAs do more than just drop numbers on a scale. Data suggests these therapies:
As lead author Dr. Samip Sheth notes, this allows for a more "integrated approach," treating the patient’s metabolic health and skin health simultaneously.
The NPF isn't suggesting GLP-1s for everyone, but they’ve identified specific "sweet spots" for dermatologists to consider:
One of the most reassuring takeaways for both doctors and patients is the safety profile. Unlike many traditional systemic treatments for psoriasis, GLP-1RAs do not cause broad immunosuppression. In fact, they are associated with a reduced risk of serious infections, making them a safe adjunctive option to use alongside existing psoriatic therapies.
Click HERE for more information